THBS2 and hepatocellular carcinoma: To evaluate the value of serum TSP-2 levels for predicting HCC occurrence in CHC patients who achieved SVR with DAAs, we selected 786 patients who fulfilled the following criteria from our multicenter prospective observational cohort: those with SVR achievement, those with complete medical records, those without a past HCC history, and those who provided agreement for serum storage (Supplementary Figure S1).